Brokerages Anticipate Syros Pharmaceuticals Inc (SYRS) Will Announce Quarterly Sales of $420,000.00

Analysts expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to announce $420,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Syros Pharmaceuticals’ earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $400,000.00. Syros Pharmaceuticals reported sales of $370,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.5%. The firm is expected to report its next quarterly earnings report on Thursday, May 9th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year sales of $1.70 million for the current financial year, with estimates ranging from $1.60 million to $2.00 million. For the next financial year, analysts expect that the firm will report sales of $1.87 million, with estimates ranging from $1.60 million to $2.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.05). The business had revenue of $0.89 million during the quarter, compared to analyst estimates of $0.40 million. Syros Pharmaceuticals had a negative return on equity of 64.43% and a negative net margin of 3,038.00%.

A number of analysts have recently weighed in on SYRS shares. BidaskClub raised Syros Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 22nd. Oppenheimer set a $13.00 price objective on Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 7th. ValuEngine cut Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. JMP Securities reissued a “mkt outperform” rating and issued a $18.00 price objective on shares of Syros Pharmaceuticals in a research report on Friday, March 8th. Finally, HC Wainwright reissued a “hold” rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a research report on Friday, March 8th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Syros Pharmaceuticals presently has an average rating of “Buy” and an average target price of $16.38.

Shares of Syros Pharmaceuticals stock traded up $0.15 during trading on Friday, reaching $7.20. The company’s stock had a trading volume of 134,605 shares, compared to its average volume of 293,357. The stock has a market capitalization of $236.44 million, a price-to-earnings ratio of -3.77 and a beta of 1.30. Syros Pharmaceuticals has a 1-year low of $5.17 and a 1-year high of $13.81.

In related news, major shareholder Venture Fund Vii L.P. Arch sold 167,503 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $7.83, for a total value of $1,311,548.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Srinivas Akkaraju bought 533,332 shares of Syros Pharmaceuticals stock in a transaction that occurred on Tuesday, April 9th. The stock was purchased at an average price of $7.50 per share, with a total value of $3,999,990.00. The disclosure for this purchase can be found here. 27.80% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of SYRS. Bank of America Corp DE raised its stake in Syros Pharmaceuticals by 205.9% in the 4th quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock worth $98,000 after acquiring an additional 11,711 shares during the last quarter. Rhumbline Advisers raised its stake in Syros Pharmaceuticals by 51.4% in the 4th quarter. Rhumbline Advisers now owns 32,406 shares of the company’s stock worth $181,000 after acquiring an additional 10,995 shares during the last quarter. MetLife Investment Advisors LLC raised its stake in Syros Pharmaceuticals by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 20,338 shares of the company’s stock worth $242,000 after acquiring an additional 7,230 shares during the last quarter. Alps Advisors Inc. raised its stake in Syros Pharmaceuticals by 30.6% in the 4th quarter. Alps Advisors Inc. now owns 77,768 shares of the company’s stock worth $433,000 after acquiring an additional 18,215 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Syros Pharmaceuticals by 8.9% in the 4th quarter. Bank of New York Mellon Corp now owns 84,537 shares of the company’s stock worth $470,000 after acquiring an additional 6,883 shares during the last quarter. Institutional investors own 67.87% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Read More: What are gap-down stocks?

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.